• SP1/ADAM10/DRP1 Axis Drives SMC-EC Crosstalk in Hypoxic PH

  2026-05-20

  This study uncovers how the SP1/ADAM10/DRP1 signaling axis mediates the communication between endothelial and smooth muscle cells under hypoxia, advancing our understanding of pulmonary artery remodeling in hypoxia-induced pulmonary hypertension. The findings highlight potential molecular targets to disrupt pathogenic cell proliferation and apoptosis, with significant implications for therapeutic intervention.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-05-20

  Anlotinib hydrochloride stands out as a potent, selective multi-target tyrosine kinase inhibitor with robust anti-angiogenic activity, enabling highly reproducible endothelial cell and tumor angiogenesis assays. This guide delivers actionable protocol enhancements, troubleshooting strategies, and data-driven insights to help cancer researchers achieve superior experimental outcomes.

• 2X Taq PCR Master Mix (with dye): Advancing DNA Repair Assay

  2026-05-19

  Explore how 2X Taq PCR Master Mix (with dye) enables high-fidelity DNA repair and genotyping workflows. This article uniquely connects molecular biology assay optimization to recent advances in colorectal cancer research.

• ATRX-Deficient Glioma Cells: Enhanced Sensitivity to RTK and

  2026-05-19

  This study identifies that ATRX-deficient high-grade glioma cells are more susceptible to receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors, especially when combined with temozolomide. Incorporating ATRX mutation status into clinical trial analyses may improve therapeutic strategies for aggressive gliomas.

• Caspase-3 Colorimetric Assay Kit: Practical Workflow Guidanc

  2026-05-18

  The Caspase-3 Colorimetric Assay Kit enables reliable, quantitative measurement of DEVD-dependent caspase-3 activity in cell and tissue lysates, supporting apoptosis and neurodegenerative disease research. It streamlines caspase activity measurement with a simple colorimetric readout and defined protocol parameters. This kit is not suited for live-cell imaging or multiplexed high-throughput screening outside its validated workflow.

• BI 2536: Precision PLK1 Inhibitor for Cell Cycle Arrest

  2026-05-18

  BI 2536 is a potent, selective PLK1 inhibitor that induces G2/M cell cycle arrest and apoptosis in cancer cells. Supported by robust in vitro and in vivo benchmarks, it enables targeted investigation of mitotic checkpoint regulation in oncology research.

• Cyclic Pifithrin-α Hydrobromide: Precision p53 Inhibition fo

  2026-05-17

  Explore the advanced use of Cyclic Pifithrin-α hydrobromide as a p53 inhibitor in neuroinflammation and radioprotection research. This article uniquely bridges mechanistic insights from novel neuroinflammatory pathways to optimized experimental protocols, offering actionable guidance for scientists utilizing this compound.

• Peroxidasin Drives Glycolysis and Progression in Glioblastom

  2026-05-16

  This study identifies peroxidasin (PXDN) as a key driver of glycolytic metabolism in glioblastoma, promoting malignancy by upregulating LDHA. Using integrative transcriptomic and functional assays, the authors reveal PXDN's potential as a diagnostic marker and therapeutic target in GBM metabolic reprogramming.

• HSC70 and TGEV M Protein: A Novel Route for Coronavirus Entr

  2026-05-15

  This study reveals a previously unrecognized mechanism by which the transmissible gastroenteritis virus (TGEV) membrane (M) protein exploits host HSC70 to facilitate viral internalization via clathrin-mediated endocytosis. The findings provide critical insight into early coronavirus infection steps and identify host-targeted intervention points for future antiviral strategies.

• Dissecting In Vitro Drug Responses: Growth Arrest vs. Cell D

  2026-05-15

  Schwartz's dissertation advances anti-cancer drug evaluation by distinguishing proliferative arrest from cell death in vitro, challenging the widespread interchangeability of viability metrics. These insights refine experimental design in oncology research, supporting more precise assessment of targeted therapies.

• Anlotinib Hydrochloride Suppresses Angiogenesis via VEGFR2,

  2026-05-14

  This article examines a foundational study demonstrating that anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, robustly inhibits angiogenesis by suppressing VEGFR2, PDGFRβ, and FGFR1 activation. The findings clarify mechanistic and experimental details essential for researchers optimizing anti-angiogenic workflows in cancer research.

• Anlotinib in IADSRCT: Case Evidence for Multi-Target TKI Eff

  2026-05-14

  This article reviews the first clinical report of anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, in treating intra-abdominal desmoplastic small round cell tumor (IADSRCT). The study provides meaningful insight into anlotinib's anti-angiogenic mechanism and its translational role in rare, aggressive sarcomas.

• Puromycin Aminonucleoside: Precision Inducer of Podocyte Inj

  2026-05-13

  Puromycin aminonucleoside is a validated nephrotoxic agent for inducing podocyte injury and modeling nephrotic syndrome in vivo and in vitro. Its defined mechanism disrupts glomerular filtration barrier integrity, enabling reproducible FSGS-like lesions and proteinuria. The compound’s uptake and cytotoxicity are quantifiable and workflow-optimized for nephrology research.

• RPN1 Loss Sensitizes TNBC to PD-L1 Blockade via Glycosylatio

  2026-05-13

  This study demonstrates that loss of RPN1 impairs PD-L1 glycosylation and stability, enhancing antitumor immunity and the efficacy of checkpoint blockade in triple-negative breast cancer. The findings establish a YY1/RPN1/YBX1 regulatory axis and highlight new mechanistic avenues for improving immunotherapy outcomes in aggressive breast cancer subtypes.

• Refining In Vitro Drug Response Assessment in Cancer Researc

  2026-05-12

  Schwartz's dissertation introduces a nuanced framework for evaluating anti-cancer agents by disentangling proliferative arrest from cell death in in vitro assays. This advancement offers researchers a clearer, quantitative understanding of drug effects, facilitating more reliable preclinical evaluation and translation.

16637 records 1/1110 page Next 12345 下5页 Last page